Close

Regeneron (REGN) Announces NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV in Outpatients at High Risk of Clinical Progression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. JBHT
2. UAL
3. SAGE
4. TSLA
5. TRV
6. ASML
7. PLD
8. OMC
9. IBKR
10. ITCI


Go back to Regeneron (REGN) Announces NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV in Outpatients at High Risk of Clinical Progression

NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression

April 9, 2021 8:15 AM EDT

TARRYTOWN, N.Y., April 9, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend that REGEN-COV (casirivimab with imdevimab)... More